title: Modulation of CNS pain circuitry by intravenous and sublingual doses of buprenorphine.
abstract: Buprenorphine (BUP) is a partial agonist at μ-, δ- and ORL1 (opioid receptor-like)/nociceptin receptors and antagonist at the κ-opioid receptor site. BUP is known to have both analgesic as well as antihyperalgesic effects via its central activity, and is used in the treatment of moderate to severe chronic pain conditions. Recently, it was shown that intravenous (IV) administration of 0.2mg/70 kg BUP modulates the blood oxygenation level-dependent (BOLD) functional magnetic resonance imaging (fMRI) response to acute noxious stimuli in healthy human subjects. The present study extends these observations by investigating the effects of BUP dose and route of administration on central nervous system (CNS) pain circuitry. Specifically, the modulation of evoked pain BOLD responses and resting state functional connectivity was measured following IV (0.1 and 0.2mg/70 kg) and sublingual (SL) (2mg) BUP administration in healthy human subjects. While 0.1mg/70 kg IV BUP is sub-analgesic, both 0.2mg/70 kg IV BUP and 2.0mg SL BUP are analgesic doses of the drug. Evoked BOLD responses were clearly modulated in a dose-dependent manner. The analgesic doses of BUP by both routes of administration yielded a potentiation in limbic/mesolimbic circuitry and attenuation in sensorimotor/sensory-discriminative circuitry. In addition, robust decreases in functional connectivity between the putamen and the sensorimotor/sensory-discriminative structures were observed at the two analgesic doses subsequent to measuring the maximum plasma BUP concentrations (C(max)). The decreases in functional connectivity within the sensorimotor/sensory-discriminative circuitry were also observed to be dose-dependent in the IV administration cohorts. These reproducible and consistent functional CNS measures at clinically effective doses of BUP demonstrate the potential of evoked pain fMRI and resting-state functional connectivity as objective tools that can inform the process of dose selection. Such methods may be useful during early clinical phase evaluation of potential analgesics in drug development.
authors: Imaging Consortium for Drug Development, PAIN Group, Brain Imaging Center, McLean Hospital, 115 Mill Street, Belmont, MA 02478, USA.
authors: Jaymin
authors: J
authors: Upadhyay
authors: Julie
authors: J
authors: Anderson
authors: Richard
authors: R
authors: Baumgartner
authors: Alexandre
authors: A
authors: Coimbra
authors: Adam J
authors: AJ
authors: Schwarz
authors: Gautam
authors: G
authors: Pendse
authors: Diana
authors: D
authors: Wallin
authors: Lauren
authors: L
authors: Nutile
authors: James
authors: J
authors: Bishop
authors: Edward
authors: E
authors: George
authors: Igor
authors: I
authors: Elman
authors: Soujanya
authors: S
authors: Sunkaraneni
authors: Gary
authors: G
authors: Maier
authors: Smriti
authors: S
authors: Iyengar
authors: Jeffrey L
authors: JL
authors: Evelhoch
authors: David
authors: D
authors: Bleakman
authors: Richard
authors: R
authors: Hargreaves
authors: Lino
authors: L
authors: Becerra
authors: David
authors: D
authors: Borsook
mesh_terms: D000286:Administration, Sublingual; D000328:Adult; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects* / Q000503:physiopathology*; D002047:Buprenorphine / Q000008:administration & dosage / Q000494:pharmacology*; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006801:Humans; D007275:Injections, Intravenous; D008279:Magnetic Resonance Imaging; D008297:Male; D010146:Pain / Q000188:drug therapy* / Q000503:physiopathology*
chemical_list: D000701:Analgesics, Opioid; D002047:Buprenorphine